9606 — Duality Biotherapeutics Balance Sheet
0.000.00%
- HK$27.60bn
- HK$23.63bn
- CNY1.94bn
Annual balance sheet for Duality Biotherapeutics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | — | — |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Cash and Equivalents | ||
| Short Term Investments | ||
| Cash and Short Term Investments | 1,131 | 1,391 |
| Net Total Accounts Receivable | ||
| Net Total Receivables | 133 | 449 |
| Prepaid Expenses | ||
| Total Other Current Assets | ||
| Total Current Assets | 1,334 | 1,910 |
| Gross Property, Plant And Equipment | ||
| Accumulated Depreciation | ||
| Net Property, Plant And Equipment | 17.8 | 18.6 |
| Net Intangible Assets | ||
| Other Long Term Assets | ||
| Total Assets | 1,500 | 2,090 |
| Accounts Payable | ||
| Notes Payable / Short Term Debt | ||
| Current Portion of Long Term Debt / Capital Leases | ||
| Total Other Current Liabilities | ||
| Total Current Liabilities | 2,561 | 3,872 |
| Capital Lease Obligations | ||
| Total Long Term Debt | ||
| Total Debt | ||
| Total Other Liabilities | ||
| Total Liabilities | 2,624 | 4,112 |
| Common Stock | ||
| Retained Earnings (Accumulated Deficit) | ||
| Other Equity | ||
| Total Equity | -1,124 | -2,022 |
| Total Liabilities & Shareholders' Equity | 1,500 | 2,090 |
| Total Common Shares Outstanding |